BioSpace News Archive

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

Vystar® Corporation (OTCQB: VYST) has named Byron Novosad, DDS, to the Vystar Board of Directors, effective immediately.

Leading Expert in Reconstructive Medicine and Burn Care and Veteran Medical Entrepreneur Join Company amid Global Expansion and Roll Out of its Novel Spincare System

Xcelerate, Inc. (OTC: UDHI) is honored to announce Barry James Marshall AC FRACP FRS FAA will join its Advisory Board, effective immediately.

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Deborah Geraghty, Ph.D., has been promoted from chief operating officer to the role of president and chief executive officer, reporting to the Board of Directors,

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division and the University of Pittsburgh Drug Discovery Institute (UPDDI) have jointly received a Phase I NIH-funded SBIR grant to combine the highly successful DSS software (DILIsym)

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced it will report its 2020 financial and operating results after the close of U.S. financial markets on Monday, March 1, 2021:

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021.

Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B Day One plans to evaluate the combination of pimasertib and DAY101, the Company’s clinical-stage pan-RAF kinase inhibitor, in patients ≥12 years of age with advanced solid tumors

Ocugen, Inc. announced that on the recommendation of the European Medicines Agency, the European Commission has granted orphan medicinal product designation for OCU400, for the treatment of both retinitis pigmentosa and Leber Congenital amaurosis.